| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/24/2000 | EP1002071A1 Human glial cell line-derived neurotrophic factor promoters, vectors containing same, and methods of screening compounds therewith |
| 05/24/2000 | EP1002065A1 Nanocrystalline formulations of human immunodeficiency virus (hiv) protease inhibitors using cellulosic surface stabilizers and methods of making such formulations |
| 05/24/2000 | EP1001984A1 NOVEL ESTROGEN RECEPTOR $g(b) AND ISOFORMS |
| 05/24/2000 | EP1001983A1 NOVEL ESTROGEN $g(b) RECEPTOR AND ISOFORMS |
| 05/24/2000 | EP1001970A1 Dipeptide derivatives as growth hormone secretagogues |
| 05/24/2000 | EP1001967A1 Componds and methods for treating and screening viral reactivation |
| 05/24/2000 | EP1001932A1 Conjugates of dithiocarbamates with pharmacologically active agents and uses therefor |
| 05/24/2000 | EP1001815A1 Vectors derived from antibodies for transferring substances into cells |
| 05/24/2000 | EP1001804A1 Pharmaceutical compositions containing lysostaphin alone or in combination with an antibiotic for the treatment of staphylococcal infections |
| 05/24/2000 | EP1001802A1 A combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor |
| 05/24/2000 | EP1001801A1 Product comprising at least a double stranded rna combined with at least an antiviral agent |
| 05/24/2000 | EP1001796A1 Antacid and papain combination |
| 05/24/2000 | EP1001789A1 Product comprising at least a double stranded rna combined with at least a 6-benzyluracil derivative |
| 05/24/2000 | EP1001784A1 Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucosidase inhibitor |
| 05/24/2000 | EP1001783A1 Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide |
| 05/24/2000 | EP1001774A1 Use of phospholamban inhibitors to increasing coronary flow |
| 05/24/2000 | EP1001771A1 A medicament against infertility and for increasing fertility |
| 05/24/2000 | EP1001765A1 Internal two photon excitation device for delivery of pdt to diffuse abnormal cells |
| 05/24/2000 | EP1001758A1 Use of a drug capable of modulating the regulation of upc-2 and method for screening for potential drugs against obesity |
| 05/24/2000 | EP1001752A1 Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals |
| 05/24/2000 | EP1001746A1 Fast-dissolving comestible units formed under high-speed/high-pressure conditions |
| 05/24/2000 | EP1001741A1 Use of amino phenol amide derivatives as depigmentation agents |
| 05/24/2000 | EP1001677A1 A novel method for treating epidermal or dermal conditions |
| 05/24/2000 | EP0720620B1 Glutathione analogs and paralog panels comprising glutathione mimics |
| 05/24/2000 | EP0626969B1 CoA-IT AND PAF INHIBITORS |
| 05/24/2000 | CN1254337A N-hydroxy 4-sulfonyl butyramide compounds |
| 05/24/2000 | CN1254335A Nicotinamide derivatives |
| 05/24/2000 | CN1254290A Genes coding proteins for early liver development and their use in diagnosing and treating liver disease |
| 05/24/2000 | CN1254281A HIV and cancer treatment |
| 05/23/2000 | US6066748 Process of extracting TAXOL® from taxus cuspidata |
| 05/23/2000 | US6066676 Pharmaceutical composition and methods for using it |
| 05/23/2000 | US6066668 Formulations and methods of reducing toxicity of antineoplastic agents |
| 05/23/2000 | US6066653 Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs |
| 05/23/2000 | US6066649 Erythro-9-(2-hydroxy-3-nonyl)-adenine or 2-o-propoxyphenyl-8-azapurine-6-one, optionally together with one or more activators of guanyl cyclase |
| 05/23/2000 | US6066648 Integrin receptor antagonists |
| 05/23/2000 | US6066645 Administering an effective amount of the protective agent to a patient receiving one or more antineoplastic agents; compounds useful as protective agents have either a sulfhydryl moiety or are reducible disulfides |
| 05/23/2000 | US6066643 Administering to said mammal an effective amount of moxonidine, or a pharmaceutically acceptable salt thereof |
| 05/23/2000 | US6066465 Measuring concentration of cyclophilins in blood sample, comparing to control, and evaluating degree of shock by increase of cytophilin concentration over control levels |
| 05/23/2000 | US6066463 Method and compositions for treatment of BCR-ABL associated leukemias and other cell proliferative disorders |
| 05/23/2000 | US6066333 Administering drug that alters heme-oxygenase activity |
| 05/23/2000 | US6066319 Administering membrane attack complex (mac) transmembrane channel forming agent which is an antibody simultaneously therewith an effective amount of a therapeutic or diagnostic agent |
| 05/18/2000 | WO2000028332A1 Methods and compositions to lower plasma cholesterol levels |
| 05/18/2000 | WO2000028323A1 Methods for identifying modulators of bs69 activity |
| 05/18/2000 | WO2000028075A1 Bacillus strain and assay methods |
| 05/18/2000 | WO2000028074A1 Screening process for antibacterial agents |
| 05/18/2000 | WO2000028059A1 Adenovirus-mediated gene therapy |
| 05/18/2000 | WO2000028045A2 Human hydrolase proteins |
| 05/18/2000 | WO2000028037A1 CATFIIIA CANDIDA ALBICANS tfIIIA GENE (CatfIIIA) AND THE CODED CATFIIIA PROTEIN |
| 05/18/2000 | WO2000028034A2 Cytokine signal regulators |
| 05/18/2000 | WO2000028029A2 Cell surface glycoproteins |
| 05/18/2000 | WO2000028022A1 Pge synthase and methods and means for modulating its activity |
| 05/18/2000 | WO2000028020A2 Methods for preventing cardiac hypertrophy and heart failure by inhibition of mef2 transcription factor |
| 05/18/2000 | WO2000027897A2 Silane copolymer coatings |
| 05/18/2000 | WO2000027879A1 Platelet-derived growth factor d, dna coding therefor, and uses thereof |
| 05/18/2000 | WO2000027864A1 CHROMOSOME 17p-LINKED PROSTATE CANCER SUSCEPTIBILITY GENE |
| 05/18/2000 | WO2000027849A2 Therapeutic polymorphs of a gaba-a alpha-5 inverse agonist and pamoate formulations of the same |
| 05/18/2000 | WO2000027792A1 Novel compounds and medicinal use thereof |
| 05/18/2000 | WO2000027434A1 Combinations comprising a beta-agonist and a further antidiabetic agent |
| 05/18/2000 | WO2000027426A1 Method for enhancing proliferation of inner ear hair cells using ligands for her2 and/or her3 receptors |
| 05/18/2000 | WO2000027422A2 Methods and compositions for treating or preventing peripheral neuropathies |
| 05/18/2000 | WO2000027414A2 Inhibition of the formation of vascular hyperpermeability |
| 05/18/2000 | WO2000027404A1 Method for treating a patient with neoplasia by treatment with an anthracycline antibiotic |
| 05/18/2000 | WO2000027400A1 Use of agonists of glucocorticosteroid receptors and/or mineral corticosteroid receptors, especially corticosteroids to treat addictions |
| 05/18/2000 | WO2000027392A1 Chromone enteric release formulation |
| 05/18/2000 | WO2000027391A1 Method for treating a patient with neoplasia by treatment with a platinum coordination complex |
| 05/18/2000 | WO2000027389A1 Oxy-vanadium (iv) complexes having spermicidal activity |
| 05/18/2000 | WO2000027387A1 Use of propionyl l-carnitine for the preparation of a medicament capable of inducing apoptosis |
| 05/18/2000 | WO2000027386A1 Use of propionylcarnitine for the manufacture of a medicament for inhibiting smooth muscle cell proliferation |
| 05/18/2000 | WO2000027385A1 Dispersible compositions containing l-dopa ethyl ester |
| 05/18/2000 | WO2000027384A1 METHOD FOR AUGMENTING THE INOTROPIC EFFECTS OF β-ADRENERGIC AGONISTS USING PYRUVATE THERAPY |
| 05/18/2000 | WO2000027383A1 Dysuria remedies |
| 05/18/2000 | WO2000027382A2 Combination of a gaba-a alpha 5 inverse agonist and cox-2 inhibitor, nsaid, estrogen or vitamin e |
| 05/18/2000 | WO2000027380A2 Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease |
| 05/18/2000 | WO2000027372A1 Pharmaceutical preparations for external use containing non-steroidal anti-inflammatory and analgesic agents |
| 05/18/2000 | WO2000027363A1 Aerosols comprising nanoparticle drugs |
| 05/18/2000 | WO2000027359A1 An inhalation system |
| 05/18/2000 | WO2000027341A2 Novel method of treatment |
| 05/18/2000 | WO2000027327A1 Hemostatic polymer useful for rapid blood coagulation and hemostasis |
| 05/18/2000 | WO2000027207A1 Compositions of restricted cells capable of rapid growth which produce proliferation suppressive materials, and uses thereof |
| 05/18/2000 | WO2000027196A1 Use of gm-csf to inhibit development of drug resistance in hiv+ patients |
| 05/18/2000 | WO2000027194A1 Method for treating a patient with neoplasia by treatment with a paclitaxel derivative |
| 05/18/2000 | WO2000027191A1 Disposable premoistened wipe containing an antimicrobial protease inhibitor |
| 05/18/2000 | WO2000009130A3 New pharmaceutical uses for nos inhibitors |
| 05/18/2000 | WO2000009108A3 Compositions and uses for vision and memory disorders |
| 05/18/2000 | WO2000007544A3 Vitronectin receptor antagonists |
| 05/18/2000 | WO2000006597A3 Endogenous constitutively activated g protein-coupled orphan receptors |
| 05/18/2000 | WO2000006140A3 Use of moclobemide for treating certain phsychiatric and medical disorders |
| 05/18/2000 | WO2000004892A3 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions |
| 05/18/2000 | WO2000000207A9 Treatment of hyperproliferative disorders |
| 05/18/2000 | WO2000000186A9 Method of treating topical ailments |
| 05/18/2000 | WO1999061467A3 Inhibition of the binding of protein tyrosine phosphatase pest to domains of signalling proteins |
| 05/18/2000 | CA2351063A1 A system for administering a bioactive agent by inhalation comprising a lipid mixture comprising phosphatidylcholine |
| 05/18/2000 | CA2351057A1 Combination of a gaba-a alpha 5 inverse agonist and cox-2 inhibitor, nsaid, estrogen or vitamin e |
| 05/18/2000 | CA2351017A1 Catfiiia candida albicans tfiiia gene (catfiiia) and the coded catfiiia protein |
| 05/18/2000 | CA2350628A1 Hemostatic polymer useful for rapid blood coagulation and hemostasis |
| 05/18/2000 | CA2350388A1 Human hydrolase proteins |
| 05/18/2000 | CA2350316A1 Methods and compositions to lower plasma cholesterol levels |
| 05/18/2000 | CA2350304A1 Dispersible compositions containing l-dopa ethyl ester |
| 05/18/2000 | CA2350087A1 Chromosome 17p-linked prostate cancer susceptibility gene |
| 05/18/2000 | CA2350086A1 Methods for preventing cardiac hypertrophy and heart failure by inhibition of mef2 transcription factor |